Authors
Latest:
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCCRobert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Latest:
Dr. Hansen on the Utilization of BCMA-Directed Therapy in Multiple MyelomaDoris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.
Latest:
Dr Landgren on the Utility of MRD as an End Point in Multiple Myeloma TrialsC. Ola Landgren, MD, PhD, discusses the utility of minimal residual disease as an end point in clinical trials for the treatment of multiple myeloma.
Latest:
Dr. Wolin on the Treatment Landscape of NETsEdward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.
Latest:
NYU Langone Health Receives Awards for Outstanding Quality & SafetyNYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc.
Latest:
Dr. Cai on Disparities in Access to Care in Breast CancerSteven Cai, MD, FACS, discusses the ongoing effort to address disparities in breast cancer care, and the importance of improving access to care for underserved patients.
Latest:
Dr. Nixon on the Role of IHC and Multiplex PCR in Detecting MSI-H TumorsAndrew B. Nixon, PhD, MBA, discusses the role of immunohistochemistry and multiplex polymerase chain reactions tests in detecting microsatellite instability–high tumors.
Latest:
Dr Perez on the Efficacy and Safety of Frontline Petosemtamab Plus Pembrolizumab in HNSCCCesar A. Perez, MD, discusses the ongoing investigation of frontline petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma.
Latest:
Dr. Juárez Soto on the Efficacy of Apalutamide Plus ADT in mHSPCÁlvaro Juárez Soto, MD, discusses the efficacy of apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Trinh on the Recovery of Cancer Screening Tests Following First COVID-19 Pandemic PeakQuoc-Dien Trinh, MD, discusses findings from a study examining the temporal changes in cancer tests and diagnoses in a large healthcare system in the United States during the COVID-19 pandemic.
Latest:
Dr. Chandra on the Need for Resources to Evaluate Racial Disparities in Prostate CancerDhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.
Latest:
Management of Hepatocellular Carcinoma: Future Directions in CareExpert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.
Latest:
Dr Gomez Arteaga on an Investigation of Orca-T Vs PTCy-Based HCT in Acute Leukemia and MDSAlexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.
Latest:
O'Neil on the Feasibility of Diagnostic CT-Enabled Planning For Patients Receiving Palliative Radiation TherapyMelissa O'Neil, MRT(T), discusses findings from the randomized phase 2 Diagnostic CT-Enabled Radiation Therapy trial of palliative radiation therapy.
Latest:
Dr Evans on the Influence on Patient Factors and Treatment Decisions in Pancreatic CancerNicole S. Evans, MD, discusses the influence of patient factors on declining treatment in pancreatic cancer.
Latest:
Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCLCraig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.
Latest:
Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD TrialAditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.
Latest:
Precision Cancer Care: Preserving Normal Tissue With Proton TherapyRadiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.
Latest:
Dr. Murthy on the Potential Benefits of Treatment De-Escalation in Ph+ B-ALLGuru Subramanian Guru Murthy, MD, MS, discusses the potential benefits of treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.
Latest:
Dr Mouabbi on Challenges Diagnosing and Managing Invasive Lobular CarcinomaJason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma
Latest:
Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCLYuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).
Latest:
Dr Goel on the Safety Profile of Tinengotinib in Solid TumorsSanjay Goel, MD, MS, discusses the safety profile of the TKI tinengotinib as a monotherapy and in combination with chemotherapy in patients with solid tumors.
Latest:
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL ManagementMinoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.
Latest:
Dr Singh on Unmet Medical Needs in Lung Cancer TreatmentRaj Singh, MD, discusses unmet medical needs in the treatment of patients with lung cancer.
Latest:
Dr. Gibbs on the Role of ctDNA in Predicting Distant vs Locoregional Recurrence in CRCPeter Gibbs, MBBS, MD, FRACP, discusses the role of circulating tumor DNA in predicting distant vs locoregional recurrence in colorectal cancer.
Latest:
Dr Martín-Broto on the Efficacy of Sunitinib Plus Nivolumab in Clear Cell SarcomaJavier Martín Broto MD, PhD, discusses the efficacy of treatment with sunitinib plus nivolumab in clear cell sarcoma, according to the IMMUNOSARC II trial.
Latest:
Dr Ricciuti on PD-L1 Expression and Long-Term Survival Outcomes With PD-L1 Inhibitors in Advanced NSCLCBiagio Ricciuti, MD, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1 monotherapy in patients with advanced non–small cell lung cancer.
Latest:
Dr. Kishan on the MIRAGE Trial of MRI-Guided SBRT in Prostate CancerAmar U. Kishan, MD, discusses interim results from the phase 3 MIRAGE trial of magnetic resonance imaging–guided stereotactic body radiotherapy in prostate cancer.
Latest:
Cytokines Play Integral Role in Cancer Immune CycleIn the setting of cancer, cytokines contribute to cells’ antitumor response, cell damage, inflammation, angiogenesis, metastasis, and other cellular processes that enable tumor survival
